Skip to main content

Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement

CBE ID
0566
Endorsement Status
1.0 New or Maintenance
1.1 Measure Structure
Previous Endorsement Cycle
Is Under Review
No
Next Maintenance Cycle
Fall 2024
1.6 Measure Description

Percentage of patients aged 50 years and older with a diagnosis of age-related macular degeneration or their caregiver(s) who were counseled within 12 months on the benefits and/or risks of the AREDS formulation for preventing progression of AMD

Note: This can be discussed with all patients with AMD, even those who do not meet the criteria for the AREDS formulation, patients who are smokers (beta-carotene can increase the risk for cancer in these patients) or other reasons why the patient would not meet criteria for AREDS formulation as outlined in the AREDS. The ophthalmologist or optometrist can explain why these supplements are not appropriate for their particular situation. Also, given the some of the purported risks associated with antioxidant use, patients would be informed of the risks and benefits and make their choice based on valuation of vision loss vs. other risks. As such, the measure seeks to educate patients about overuse as well as appropriate use.

    Measure Specs
      General Information
      1.7 Measure Type
      1.3 Electronic Clinical Quality Measure (eCQM)
      1.20 Types of Data Sources
      1.14 Numerator

      Patients with AMD or their caregiver(s) who were counseled within 12 months on the benefits and/or risks of the AREDS formulation for preventing progression of AMD

      1.15 Denominator

      All patients aged 50 years and older with a diagnosis of age-related macular degeneration

      Exclusions

      Not applicable.

      Most Recent Endorsement Activity
      Endorsed EENT Endorsement Maintenance Project 2014
      Initial Endorsement
      Last Updated
      Steward Organization
      American Academy of Ophthalmology
      Steward POC email
                Public Comments